Drug Information

Drug General Information
Drug ID
D02FIJ
Former ID
DIB009620
Drug Name
FK-224
Synonyms
FR-115224
Drug Type
Small molecular drug
Indication Asthma [ICD10:J45] Discontinued in Phase 2 [539332], [544903]
Company
Fujisawa Pharmaceutical Co Ltd
Structure
Download
2D MOL

3D MOL
Formula
C54H72N8O13
InChI
InChI=1S/C54H72N8O13/c1-7-8-10-17-36-18-13-14-19-37(36)22-25-45(67)60-47-33(5)75-54(74)42(30-63)59-49(69)41(29-44(55)66)58-52(72)46(32(4)64)61-50(70)40(27-34-15-11-9-12-16-34)56-48(68)39(26-31(2)3)57-51(71)43(62(6)53(47)73)28-35-20-23-38(65)24-21-35/h9,11-16,18-21,23-24,28,31-33,39-42,46-47,63-65H,7-8,10,17,22,25-27,29-30H2,1-6H3,(H2,55,66)(H,56,68)(H,57,71)(H,58,72)(H,59,69)(H,60,67)(H,61,70)/b43-28-
InChIKey
BEWCDVTWUFJSSM-MBMPTNJISA-N
CAS Number
CAS 125787-94-2
PubChem Compound ID
6437864
PubChem Substance ID
43030917, 57367928, 78699187, 85211521, 114554631, 135072796, 135652683, 136351054, 179293912
Target and Pathway
Target(s) Substance-P receptor Target Info Modulator [526798]
NK-2 receptor Target Info Modulator [526798]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Measleshsa04020:Calcium signaling pathway
PANTHER Pathway CCKR signaling map ST
Reactome G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling events
WikiPathways SIDS Susceptibility Pathways
Gastrin-CREB signalling pathway via PKC and MAPK
Spinal Cord Injury
Peptide GPCRs
GPCR ligand binding
GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK
GPCR downstream signaling
References
Ref 539332(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2103).
Ref 544903Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001455)
Ref 526798FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther. 1992 Jul;262(1):398-402.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.